Overall number of NK cells correlates with number but not the proportion of each NK developmental stage. (A) Absolute number of circulating CD56^brightCD117⁺NKG2A⁻ stage III NK cells. (B) Absolute number of circulating stage IV CD56^brightCD117⁺ (left, R = 0.85, 95% CI: 0.77-0.90; P < .01) and CD56^brightCD117⁻ (right, R = 0.77, 95% CI: 0.66-0.85; P < .01) NK cells. (C) Absolute number circulating of CD56^dimNKG2A⁺ stage V (left, R = 0.86, 95% CI: 0.80-0.91; P < .01), CD56^dimKIR⁺ stage V (middle, R = 0.77, 95% CI: 0.66-0.84; P < .01), and CD56^dimCD57⁻ stage V (right, R = 0.77, 95% CI: 0.66-0.84; P < .01) NK cells. (D) Absolute number of circulating CD56^dimCD57⁺ stage VI NK cells (R = 0.95, 95% CI: 0.92-0.97; P < .01). (E) Proportion of stage III NK cells. (F) Proportion of stage IV CD56^bright CD117⁺ (left) and CD56^brightCD117⁻ (right) NK cells. (G) Proportion of NKG2A⁺ stage V (left), KIR⁺ stage V (middle), and CD56^dimCD57⁻ stage V (left) NK cells. (F) Proportion of CD56^dimCD57⁺ stage VI NK cells. R = Spearman correlation coefficients. Data represented as a data point for each patient with the mean of the population as the solid middle line with standard error above and below. Healthy donor controls for panels E-H are represented by the mean (dashed line) and standard error (gray box). The absolute number of each population was calculated by multiplying the proportion of each NK differentiation stage by the absolute number of NK cells. *R = ±0.25-0.50; **R = ±0.50-0.8; ***R > ±0.8.